Dr. Stephen Krieger: “New Data, New Drugs, and...a Vitamin for MS?”
Stephen Krieger, MD, sits down with Bruce Cree to discuss multiple sclerosis (MS) highlights from the 67th Annual American Academy of Neurology meeting in Washington, DC. “This was a great meeting. We heard a lot of results from research in MS that will be important for us over the coming years,” says Dr. Krieger, “For example, we heard the daclizumab clinical trial results. This was a phase 3 trial, a direct comparison with weekly intramuscular interferon injection. Daclizumab is a new candidate medicine for MS, with a new mechanism of action. It was superior to interferon in preventing relapses, preventing MRI lesions, and even preventing the accumulation of disability. It was positive on all three of those metrics.” Learn more
Scientists Develop Novel Approach to Enhance Drug Delivery for Brain Tumors in Children
Mar 02, 2023 View All Press Releases
Researchers Identify the Role of an Alzheimer’s Disease Risk Gene in the Brain
Nov 30, 2022 View All Press Releases
